Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.19.2
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Revenue from contract with customer $ 16,000   $ 264,000   $ 30,000 $ 265,000  
Grant and other revenue 244,199   277,753   282,673 553,403  
Revenue 260,092   542,127   301,716 818,572  
Cost of revenue 238   35,392   6,364 35,710  
Research and development expenses 1,070,642   1,142,718   1,811,225 2,141,674  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,824,874   1,751,888   3,516,611 3,490,273  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 36,726   37,511   73,505 75,498  
Loss from operations [3] (2,672,388)   (2,425,382)   (5,105,989) (4,924,583)  
Other income (expense) [4] (1,590)   (20,719)   7,122 (4,259,480)  
Income tax benefit 168   10,929   (708) 10,929  
Net loss from continuing operations (2,673,810)   (2,435,172)   (5,099,575) (9,173,134)  
Income from discontinued operations, net of tax 632   (1,938)   (2,665) (1,938)  
Net income (loss) (2,673,178) $ (2,429,061) (2,394,057) $ (6,737,962) (5,102,240) (9,132,019)  
Total assets, net of depreciation and amortization 8,130,395       8,130,395   $ 7,021,527
Capital expenditures   3,165   3,165  
Gain on sale of discontinued operations, net of tax   43,053   43,053  
UNITED STATES              
Total assets, net of depreciation and amortization 8,123,881   8,636,954   8,123,881 8,636,954  
Non-US [Member]              
Total assets, net of depreciation and amortization 6,514   23,538   6,514 23,538  
Royalty [Member]              
Revenue from contract with customer 5,940   6,665   9,090 7,460  
License [Member]              
Revenue from contract with customer 9,953   257,709   9,953 257,709  
Diagnostics Segment [Member]              
Grant and other revenue 196,630   156,889   232,621 389,325  
Revenue 212,523   421,263   251,664 654,494  
Cost of revenue 238   35,392   6,364 35,710  
Research and development expenses 775,462   913,158   1,516,045 1,698,169  
Selling, general and administrative expenses, excluding depreciation and amortization [1]      
Depreciation, Depletion and Amortization, Nonproduction, Total [2]      
Loss from operations [3] (563,177)   (527,287)   (1,270,745) (1,079,385)  
Other income (expense) [4]      
Income tax benefit 35   2,356   (177) 1,284  
Net loss from continuing operations (563,142)   (524,931)   (1,270,922) (1,078,101)  
Income from discontinued operations, net of tax 632   (1,938)   (2,665) (1,938)  
Net income (loss) (562,510)   (483,816)   (1,273,587) (1,036,986)  
Capital expenditures      
Gain on sale of discontinued operations, net of tax     43,053     43,053  
Diagnostics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 220,334   409,769   220,334 409,769  
Diagnostics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization 6,514   22,147   6,514 22,147  
Diagnostics Segment [Member] | Royalty [Member]              
Revenue from contract with customer 5,940   6,665   9,090 7,460  
Diagnostics Segment [Member] | License [Member]              
Revenue from contract with customer 9,953   257,709   9,953 257,709  
Therapeutics Segment [Member]              
Grant and other revenue 47,569   120,864   50,052 164,078  
Revenue 47,569   120,864   50,052 164,078  
Cost of revenue      
Research and development expenses 295,180   229,560   295,180 443,505  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 3,062   16,630   14,776 25,237  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]      
Loss from operations [3] (250,673)   (125,326)   (259,904) (304,664)  
Other income (expense) [4]      
Income tax benefit 16   560   (36) 363  
Net loss from continuing operations (250,657)   (124,766)   (259,940) (304,301)  
Income from discontinued operations, net of tax      
Net income (loss) (250,657)   (124,766)   (259,940) (304,301)  
Capital expenditures      
Gain on sale of discontinued operations, net of tax          
Therapeutics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 11,235   87,751   11,235 87,751  
Therapeutics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization      
Therapeutics Segment [Member] | Royalty [Member]              
Revenue from contract with customer      
Therapeutics Segment [Member] | License [Member]              
Revenue from contract with customer      
Corporate Segment [Member]              
Grant and other revenue        
Revenue      
Cost of revenue      
Research and development expenses      
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,821,812   1,735,258   3,501,835 3,465,036  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 36,726   37,511   73,505 75,498  
Loss from operations [3] (1,858,538)   (1,772,769)   (3,575,340) (3,540,534)  
Other income (expense) [4] (1,590)   (20,719)   7,122 (4,259,480)  
Income tax benefit 117   8,013   (495) 9,282  
Net loss from continuing operations (1,860,011)   (1,785,475)   (3,568,713) (7,790,732)  
Income from discontinued operations, net of tax      
Net income (loss) (1,860,011)   (1,785,475)   (3,568,713) (7,790,732)  
Capital expenditures   3,165   3,165  
Gain on sale of discontinued operations, net of tax          
Corporate Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 7,892,312   8,139,434   7,892,312 8,139,434  
Corporate Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization   1,391   1,391  
Corporate Segment [Member] | Royalty [Member]              
Revenue from contract with customer      
Corporate Segment [Member] | License [Member]              
Revenue from contract with customer      
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($36,726 and $37,511 for the three-month periods ended June 30, 2019 and 2018, and $73,505 and $75,498 for the six-month periods ended June 30, 2019 and 2018, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.